Pfizer Talzenna — Revenues: increased by 2.0% to $50.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $40.00M to $50.00M. Over 3 years (FY 2022 to FY 2025), Talzenna — Revenues: shows an upward trend with a 55.9% CAGR.
pfe_segment_talzenna_revenues| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.00M | $12.00M | $12.00M | $12.00M | $10.00M | $12.00M | $20.00M | $22.00M | $23.00M | $32.00M | $36.00M | $26.00M | $40.00M | $46.00M | $47.00M | $49.00M | $50.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -16.7% | +20.0% | +66.7% | +10.0% | +4.5% | +39.1% | +12.5% | -27.8% | +53.8% | +15.0% | +2.2% | +4.3% | +2.0% |
| YoY Change | — | — | — | — | -16.7% | +0.0% | +66.7% | +83.3% | +130.0% | +166.7% | +80.0% | +18.2% | +73.9% | +43.8% | +30.6% | +88.5% | +25.0% |